Abstract
Randomized controlled clinical trials (RCTs) occupy a pivotal position in assessing the effectiveness of treatments for skin disease. The rudiments of the experimental design allow for control of selection, performance, detection, and attrition bias, and prospective trial registration offers further protection against selective reporting outcome bias and publication bias (Williams and Dellavalle, 2012). Clinical trials are the backbone of systematic reviews of clinical interventions, treatment guidelines, and drug licensing submissions. Cost-effectiveness studies in relation to RCTs are also essential for informing commissioning decisions in countries with state-funded health care, such as those undertaken by the UK National Institute of Health and Clinical Excellence. Despite their potential in reducing treatment uncertainties in dermatology, the usefulness of RCTs is limited by two factors: (i) the quality of design and reporting and (ii) the clinical question that the trials address.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
